

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number  
**WO 2004/016742 A2**

- (51) International Patent Classification<sup>7</sup>: C12N (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/US2003/025199
- (22) International Filing Date: 13 August 2003 (13.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/403,405 14 August 2002 (14.08.2002) US
- (71) Applicant (*for all designated States except US*): IM-MERGE BIOTHERAPEUTICS, INC. [US/US]; 300 Technology Square, Cambridge, MA 02139 (US).
- (71) Applicant and
- (72) Inventor: HAWLEY, Robert, J. [US/US]; 46 Davelin Road, Wayland, MA 01778 (US).
- (74) Agent: KEOWN, Wayne, A.; Keown & Associates, 500 West Cummings Park, Suite 1200, Woburn, MA 01801 (US).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 2004/016742 A2

(54) Title:  $\alpha(1,3)$ -GALACTOSYLTRANSFERASE NULL CELLS, METHODS OF SELECTING AND  $\alpha(1,3)$ -GALACTOSYLTRANSFERASE NULL SWINE PRODUCED THEREFROM

(57) Abstract: The invention relates to the genetic manipulation of non-human animals. More particularly, the invention relates to genetic manipulation of non-human animals to be used for xenotransplantation. The invention provides a method of selecting GGTA 1 null cells, a viable GGTA 1 null swine, methods for making such swine, and methods of using cells, tissues and organs of such swine for xenotransplantation.

BEST AVAILABLE COPY

**$\alpha(1,3)$ -GALACTOSYLTRANSFERASE NULL CELLS, METHODS  
OF SELECTING AND  $\alpha(1,3)$ -GALACTOSYLTRANSFERASE  
NULL SWINE PRODUCED THEREFROM**

(Atty Docket No. IMM-002PC )

5        This invention has been funded in part by the National Institutes of Health  
NCRR via R44 RR15198. The U.S. government has rights in this invention.

**BACKGROUND OF THE INVENTION**

**Field of the invention**

The invention relates to the genetic manipulation of non-human animals.

10    More particularly, in some embodiments, the invention relates to selecting  $\alpha(1,3)$ -  
galactosyltransferase (GGTA1) null cells and genetic manipulation of non-human  
animals to be used for xenotransplantation.

**Summary of the related art**

15    Clinical transplantation has become one of the major treatments for end stage  
organ failure since the introduction of chronic immunosuppressive drugs in the mid  
1980s. This success has brought about the secondary issue of human organ supply,  
which greatly limits the ability to provide organs to patients in need of transplants.  
One of the major approaches to solving this medical need is the utilization of  
alternative species as a source of organs (xenotransplantation). R.W Evans, in  
20    *Xenotransplantation*, J.L. Platt, Ed. (ASM Press, Washington, DC, 2001), pp. 29-51,  
teaches that the pig is the primary alternative species due to ethical considerations,  
breeding characteristics, infectious disease concerns and its compatible size and  
physiology.

25    A major barrier to progress in pig-to-primate organ transplantation is the  
presence of terminal  $\alpha(1,3)$ -galactosyl-(gal)-epitopes on the surface of pig cells.  
Humans and Old World monkeys have lost the corresponding galactosyltransferase  
activity in the course of evolution and therefore produce preformed natural antibodies

against the epitopes that are responsible for hyperacute rejection of porcine organs. The temporary removal of recipient anti-gal antibodies through affinity adsorption and expression of complement regulators in transgenic pigs has allowed survival of pig organs beyond the hyperacute rejection stage. However, D. Lambrigts, D.H. Sachs, D.K.S Cooper, *Transplantation* 66, 547 (1998), teaches that returning antibody and residual complement activity are likely to be responsible for the acute and delayed damage which severely limits organ survival even in the presence of high levels of immunosuppressive drugs and other clinical intervention. Attempts have also been made to prevent rejection by reducing expression of gal epitopes through genetic engineering of the donor animal. Unfortunately, C. Costa *et al.*, *FASEB J.* 13, 1762 (1999), discloses that competitive inhibition of galtransferase in H-transferase transgenic pigs results in only partial reduction in epitope numbers. Other similar approaches have been disclosed in Sandrin *et al* US Patent 5,821,117, Diamond *et al* US Patent 6,166,288, and Cooper *et al* US Patent 6,331,658, all teaching methods for masking the gal epitope through the genetically modified increased expression of carbohydrate epitopes. Similarly, S. Miyagawa *et al.*, *J. Biol. Chem.* 276, 39310 (2001), teaches that attempts to block expression of gal epitopes in N-acetylglucosaminyltransferase III transgenic pigs also results in only partial reduction of gal epitopes numbers and fails to significantly extend graft survival in primate recipients. Given the large number of gal epitopes present on pig cells, it seems unlikely that any dominant transgenic approach of this nature can provide sufficient protection from anti-gal mediated damage.

A.D. Thall, P. Maly, J.B. Lowe, *J. Biol. Chem.* 270, 21,437 (1995), and D'Aspice *et al*, United States Patent 5,849,991 teach that viable GGTA1 knockout mice can be produced using ES cell technology. K.L. McCreath *et al.*, *Nature* 405, 1066 (2000), and Denning *et al.* PCT Publication WO 01/88096 teach that nuclear transfer technology can be used for locus specific modification of certain large animals, as demonstrated by the production of viable sheep using *in vitro* targeted somatic cells. K.W. Park *et al.*, *Anim. Biotech.* In press (2001), discloses successful

cloning and production of transgenic pigs by nuclear transfer of genetically modified somatic cells. Gustafsson and Sachs, U.S. Patent No. 6,153,428 (2000), discloses genetically modified porcine cells *in vitro* in which the GGTA1 gene has been disrupted by homologous recombination. Dai et al, *Nature Biotechnol.* **20** (3): 251-255 (2002) teaches production of a pig heterozygous for GGTA1 disrupted gene and Lai et al, *Science*. **295**: 1089 (2002) teaches production of a miniature swine heterozygous for GGTA1 disrupted gene. Gustaffson *et al.* United States Patent 6,413,769 teaches the use of a synthetic antisense oligonucleotide (S-oligonucleotides) to create inactivated heterozygous GGTA1 disrupted miniature porcine cells. Gustaffson *et al.* further teaches the generation of heterozygous miniature swine by using a drug selection system whereby a vector delivers an antibacterial resistant sequence i.e. neomycin resistant, into the genome to render the GGTA1 gene inactivated. Unfortunately, Bondioli *et al.*, *Mol. Reproduc. Dev.* **60**: 189-195 (2001) reports that the attempt to use nuclear transfer technology to accomplish this in pigs *in vivo* has been unsuccessful. This is further reported by Ioannu et al, PCT publication WO 97/16064 which discloses that a knockout pig cannot be done.

Gustaffson further discloses in United States Patent 6,413,769 the possibility of using antisense technology to produce a miniature swine functionally unable to produce  $\alpha(1,3)$ -galactosyltransferase and a method for generation of homozygous miniature swine using a second drug selection system such as herpes simplex virus-thymidine kinase (HSV-tk). Unfortunately, he does not demonstrate that a viable homozygous swine was produced using either method and does not demonstrate that cells were able to be produced and validated for GGTA1 disrupted gene.

There is, therefore, a need for viable GGTA1 null swine defined as swine which do not express any GGTA1 epitopes and which include but are not limited to swine having both alleles of the GGTA1 gene disrupted or rendered non-functional; and swine having one copy of the GGTA1 allele instead of the usual two alleles for the GGTA1 gene and the said copy of the GGTA1 allele is disrupted or rendered non-

functional. There is also a need for methods for making such GGTA1 null swine; and methods of using the tissues and organs of such GGTA1 null swine for xenotransplantation.

**BRIEF SUMMARY OF THE INVENTION**

The invention provides viable GGTA1 null swine, methods to produce such swine, including the breeding of two GGTA1 null swine to produce GGTA1 null swine progeny, and methods of using cells, tissues and organs of such swine for  
5 xenotransplantation.

In a first aspect, the invention provides viable GGTA1 null swine. Such swine are useful as a source of organs, tissues, and cells for xenotransplantation. Such swine are also useful for providing a clearer evaluation of approaches currently in development aimed at overcoming potential delayed and chronic rejection  
10 mechanisms in porcine xenotransplantation.

In a second aspect, the invention provides a method of selecting GGTA1 null cells comprising obtaining a line of cells from a heterozygous GGTA1 swine or swine fetus in which one allele of the GGTA1 gene has been disrupted or rendered non-functional; enriching the cell line for GGTA1 null cells, and scanning said cell line for  
15 viable GGTA1 null cells.

In a third aspect, the step of enriching the cell line for GGTA1 null cells is accomplished by at least one treatment selected from the group consisting of: treating said line with anti-galactose- $\alpha$  (1,3)-galactose antibodies in the presence of complement; depleting the line using magnetic beads which are preferably bound with  
20 an anti-gal reagent such as an antibody or lectin; treating said line with anti-galactose- $\alpha$  (1,3)-galactose antibodies and then depleting the line using magnetic beads bound to an anti-antibody; and treating said line with gal epitope ligands and then depleting said line with magnetic beads coated with anti ligand antibodies. Such GGTA1 null cell enriching treatment can comprise multiple treatments selected from the group  
25 above.

In a fourth aspect, the invention provides a GGTA1 null porcine cell. Such cells lack the galactose- $\alpha$ (1,3)-galactose epitopes and are useful in overcoming hyperacute rejection in primates.

5 In a fifth aspect, the invention provides porcine organs lacking expression of galactose- $\alpha$ (1,3)-galactose epitopes and comprising GGTA1 null cells. Such organs are useful in overcoming hyperacute rejection in primates.

In a sixth aspect, the invention provides porcine tissues lacking expression of galactose- $\alpha$ (1,3)-galactose epitopes and comprising GGTA1 null cells. Such tissues are useful in overcoming hyperacute rejection in primates.

10 In a seventh aspect, the invention provides a method of creating a viable GGTA1 null swine comprising isolating GGTA1 null cells, enucleating an oocyte, fusing the oocyte with the disrupted cell to yield an NT-derived embryo, and implanting the NT-derived embryo into a surrogate mother, wherein the surrogate mother has initiated estrus, but has not yet completed ovulation.

15 In an eighth aspect, the invention provides a method of creating a viable GGTA1 null swine comprising enucleating an oocyte, fusing the oocyte with a cell derived from Q2 to yield an NT-derived embryo, and implanting the NT-derived embryo into a surrogate mother, wherein the surrogate mother has initiated estrus, but has not yet completed ovulation

20 In a ninth aspect, the invention provides a method of creating a viable GGTA1 null swine comprising enucleating an oocyte, fusing the oocyte with a cell derived from Q9 to yield an NT-derived embryo, and implanting the NT-derived embryo into a surrogate mother, wherein the surrogate mother has initiated estrus, but has not yet completed ovulation.

25 In a tenth aspect, the invention provides a method of creating a viable GGTA1 null swine comprising enucleating an oocyte, fusing the oocyte with a cell derived

from Q32 to yield an NT-derived embryo, and implanting the NT-derived embryo into a surrogate mother, wherein the surrogate mother has initiated estrus, but has not yet completed ovulation.

- In an eleventh aspect, the invention provides a method of creating a viable
- 5 GGTA1 null swine comprising enucleating an oocyte, fusing the oocyte with a cell derived from Q37 to yield an NT-derived embryo, and implanting the NT-derived embryo into a surrogate mother, wherein the surrogate mother has initiated estrus, but has not yet completed ovulation.



### **BRIEF DESCRIPTION OF THE DRAWINGS**

**Fig. 1.** Flow cytometric analysis of wild-type (F12) and GGTA1 heterozygous (355-F3) fetal cells following multiple rounds of selection with antibody and complement. Cells were analyzed prior to (open traces) or following (filled traces) staining with  $\alpha(1,3)$ -gal epitope specific lectin IB4. Cells were analyzed 5-9 days following each selection. Post treatment analyses were performed 17 days following the last selection for F12 cells, and 22 days following the last selection for 355-F1 cells. The percentage of cells recovered immediately following antibody/complement selection is indicated, and includes all cell losses during the treatment procedure.

**Fig. 2.** Flow cytometric analysis of clones Q2 and Q9, derived by antibody/complement selection of GGTA1 heterozygous cells from fetus 355-F1. Selected clones were analyzed prior to and following staining with  $\alpha(1,3)$ -gal epitope specific lectin IB4 and compared with staining of the parental fetal cell lines without antibody/complement selection. Very low level staining of the selected clones is seen, possibly due to background binding to non-gal epitopes.

**Fig. 3A.** RT-PCR analysis of clones Q2 and Q9, derived by antibody/complement selection of GGTA1 heterozygous cells from fetus 355-F1. Lane 1: Q2. Lane 2: Q9. Lane 3: F12 (WT fetal fibroblast control). Lane 4: 355-F1 cells prior to antibody/complement selection. Lambda Hind III marker sizes are indicated in kbp. 2472 bp targeted locus and 1421 bp wild-type locus PCR products are detected in 355-F1 cells prior to selection, but only the 2472 bp product is detected in clones Q2 and Q9.

**Fig. 3B.** Genomic analysis of clones Q2 and Q9, derived by antibody/complement selection of GGTA1 heterozygous cells from fetus 355-F1. Lanes 1-4: 3' targeting analysis. Lane 1: Q2. Lane 2: Q9. Lane 3: F505 (WT fetal fibroblast control). Lane 4: 355-F1 cells prior to antibody/complement selection. Lambda Hind III marker sizes are indicated in kbp. 2.3 kbp targeted locus and 1.25

5 kbp wild-type locus PCR products are detected in 355-F1 cells prior to selection, but only the 2472 bp product is detected in clones Q2 and Q9. Lanes 6-9: 5' targeting analysis. Lane 6: Q2. Lane 7: Q9. Lane 8: F505 (WT fetal fibroblast control). Lane 9: 355-F1 cells prior to antibody/complement selection. 3.6 kbp targeted locus and 2.55

5 kbp wild-type locus PCR products are detected in 355-F1 cells prior to selection, but only the 2472 bp product is detected in clones Q2 and Q9.

**Fig. 4.** Quantitative southern blot analysis of nuclear transfer donor lines. Genomic DNA from the indicated sources was digested with restriction enzyme Afl III and hybridized simultaneously with a 116 bp probe from exon 9 of the GGTA1 locus and a 107 bp probe from the DQ $\beta$  locus (as an internal quantitation control). The GGTA1 probe hybridizes a 1.3 kb wt fragment and a 2.3 kb gene targeted band containing an IRES-neo selection cassette. The F7 sample was prepared from fibroblasts of a wild-type fetus. The 355-F1 sample was prepared from GGTA1 heterozygous fetal fibroblasts prior to selection with natural antibody and complement. The 355-F1 4X sample was prepared from a cell population selected four times with affinity purified baboon natural antibody and complement. Q series samples were from clonal cell lines selected from 355-F1 fetal fibroblasts. The wild-type GGTA1 allele is not detected in the uncloned 4X selected population or in any of the four Q clones.

20 **Fig. 5.** Southern blot analysis of GGTA1 null piglets. Analysis was performed as described in the legend to Figure 4. Neither piglets O177-1 nor piglet O177-2 contains a wild-type allele of the GGTA1 gene.

**Fig. 6.** Flow cytometry analysis of  $\alpha(1,3)$ -gal epitopes on GGTA1 null piglet O177-1. Unfixed, cultured fibroblasts from piglet O177-1, heterozygous fetus 355-F1 and wild-type fetus F7 were stained with FITC conjugated IB4 prior to flow analysis. Normal human dermal fibroblasts (NHDF) and unstained O177-1 fibroblasts (-) were used as a negative controls.

**Fig 7.** Piglet O177-1 at two months of age.

**Fig 8.** Flow cytometry analysis of  $\alpha(1,3)$ -gal epitopes on cell clones derived from heterozygous cells following depletion with IB4-FITC and anti-FITC magnetic beads. Analysis of clones 15541.25 and 15541.63 is shown with (+) and without (-) IB4-FITC staining.

5       **Fig. 9.** Genomic analysis of clones 15541.25 and 15541.63, derived by IB4-FITC/ magnetic bead depletion of GGTA1 heterozygous cells from piglet 15541. 3' targeting analysis was performed as described for Figure 3B. Lane 1: Molecular weight markers, sizes are indicated in kbp. Lane 2: Wild-type fetus F3. Lane 3: Heterozygous sow O226-1, mother of piglet 15541. Lane 4: Wild-type boar 14925, father of piglet 15541. Lane 5: Heterozygous piglet 15541. Lane 6: Clonal cell line 15541.25, cloned from 15541 cells following magnetic bead depletion of 15541 cells. Lane 7: Clonal cell line 15541.63, cloned from 15541 cells following magnetic bead depletion of 15541 cells. A 2.3 kbp targeted locus and 1.25 kbp wild-type locus PCR products are detected in 15541 cells prior to selection, but only the 2472 bp product is  
10 detected in clone 15541.63. Clone 15541.25 yields products consistent with one targeted allele and one allele similar in size to a wild-type allele.  
15

**Fig. 10.** Flow cytometry analysis of PFI510 NullB cells, with and without IB4-FITC staining.

**Fig 11.** Piglet PL751 at 4 days of age.

20       **Fig 12.** Genomic analysis of piglet PL751 3' targeting analysis was performed as described for Figure 3B. Lane 1: Molecular weight markers, sizes are indicated in kbp. Lane 2: No DNA. Lane 3: Heterozygous fetus PFI510. Lane 4: Wild-type fetus F505. Lane 5: GGTA1 heterozygous control cell line PED D.13. Lane 6: No DNA. Lane 7: Piglet PL751. Only the 2472 bp product derived from a  
25 gene targeted allele is detected in the piglet.

**Fig 13.** Flow cytometry analysis of ear fibroblasts from piglet PL751, with and without IB4-FITC staining.

### **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**

The invention relates to the genetic manipulation of non-human animals. More particularly, the invention relates to genetic manipulation of non-human animals to be used for xenotransplantation. The invention provides viable GGTA1 null swine,  
5 methods for making such swine, including the breeding of two GGTA1 null swine to produce GGTA1 null swine progeny, and methods of using cells, tissues and organs of such swine for xenotransplantation.

The patents and publications cited herein reflect the knowledge in the art and are hereby incorporated by reference in their entirety. Any inconsistency between these  
10 patents and publications and this specification shall be resolved in favor of the latter.

In a first aspect, the invention provides a viable GGTA1 null swine. For the purposes of the invention "GGTA1 null swine" are swine which do not express any GGTA1 epitopes and which include but are not limited to swine having both alleles of the GGTA1 gene disrupted or rendered non-functional; and swine having one copy of  
15 the GGTA1 allele instead of the usual two alleles for the GGTA1 gene and the said allele is disrupted or rendered non-functional. By "disrupted gene" is meant a portion of the genetic code that has been altered, thereby affecting transcription and/or translation of that segment of the genetic code, *e.g.*, rendering that segment of the code unreadable through knockout techniques or by insertion of an additional gene for  
20 a desired protein or insertion of a regulatory sequence that modulates transcription of an existing sequence. In certain embodiments, the GGTA1 allele is altered by homologous recombination or other insertion or deletion. In certain embodiments, the GGTA1 allele is non-functional due to mutation.

In certain embodiments, the GGTA1 null swine is a swine in which, both alleles  
25 of the GGTA1 gene are disrupted or rendered non-functional, herein referred to as "homozygous". Such embodiments include those commonly referred to as "gene knockouts", "gene knock-ins" and any other modification of both native alleles of the native GGTA1 gene that renders such gene non-functional.

In certain embodiments, the GGTA1 null swine is a swine which only has one allele of the GGTA1 gene instead of possessing the usual two GGTA1 alleles, herein referred to as "hemizygous" and the single allele of the GGTA1 gene is disrupted or rendered non-functional.

- 5        In certain embodiments, the GGTA1 null swine is a "compound heterozygote" for the GGTA1 gene, in which the swine possesses two different mutant alleles for the GGTA1 gene, so that the GGTA1 gene is rendered non-functional.

In certain preferred embodiments, the GGTA1 null swine is a miniature swine. In certain preferred embodiments, the GGTA1 null swine is a miniature swine which  
10 is a descendant from the miniature swine disclosed in Sachs *et al.*, *Transplantation* 22, 559(1976).

Such GGTA1 null swine are useful as a source of organs, tissues and cells for xenotransplantation. Such swine are also useful for providing a clearer evaluation of approaches currently in development aimed at overcoming potential delayed and  
15 chronic rejection mechanisms in porcine xenotransplantation.

In a second aspect, the invention provides a method of selecting GGTA1 null cells comprising obtaining a line of cells from a heterozygous GGTA1 swine or swine fetus in which one allele of the GGTA1 gene has been disrupted or rendered non-functional; enriching the cell line for GGTA1 nulls cells, and scanning said cell line  
20 for viable GGTA1 null cells. For the purposes of the invention, "scanning" means any method used to validate the presence of the disrupted gene. Methods of such scanning are well known to those skilled in the art and include but are not limited to staining with lectins, flow cytometry, PCR, RT-PCR and Southern Blots. For the purposes of the invention a "line" is a group of cells derived from the same source.  
25 Methods of obtaining such lines are well known to those skilled in the art. One non-limiting example of obtaining a line includes isolation of primary fibroblasts from miniature swine fetus by collagenase/trypsin digestion of minced tissue, plating the dissociated cells on collagen-coated plates in nutrient medium containing one or more

reagents such as Hams F10 medium, Dulbecco's Modified Eagle's Medium (DMEM), Fetal Bovine Serum (FBS), and antibiotics such as gentamycin, adherent cells are then cryopreserved and function as the "line". In certain preferred embodiments, the heterozygous GGTA1 swine is a miniature swine and is produced according to the methods disclosed in Lai *et al*, *Science* **295**:1089 (2002). In certain preferred embodiments, the heterozygous GGTA1 swine is a miniature swine, which is a descendant of the miniature swine disclosed in Sachs *et al*, *Transplantation* **22**, 559 (1976). In certain preferred embodiments, the swine fetus with one disrupted GGTA1 allele is obtained from a descendant of the miniature swine disclosed in Sachs *et al*, *Transplantation* **22**, 559 (1976).

In certain preferred embodiments, the line of cells is obtained by isolating GGTA1 heterozygous cells from a nuclear transfer fetus after gestation and culturing the said cells as described in Lai *et al*., *Science* **295**:1089 (2002). In certain preferred embodiments, the line of cells is a clonal population of porcine fetal fibroblast cells. For the purposes of the invention a "clonal population" is a group of cells derived from a single cell. Porcine fetal fibroblast cells of the invention may be obtained through techniques known to those skilled in the art and include but are not limited to mincing porcine fetal tissue and digestion of tissue with collagenase and trypsin. In certain preferred embodiments the porcine fetal fibroblasts cells are obtained from miniature swine descendant from the miniature swine disclosed in Sachs *et al*., *Transplantation* **22**, 559(1976). In certain preferred embodiments the porcine fetal fibroblasts cells are heterozygous for a GGTA1 knockout. In preferred embodiments the cells heterozygous for a GGTA1 knockout are obtained from descendants from the miniature swine disclosed in Lai *et al*., *Science* **295**:1089 (2002).)

In a third aspect, the step of enriching the cell line for GGTA1 null cells described in the second aspect is accomplished by at least one treatment selected from the group consisting of: treating said line with anti-galactose- $\alpha$  (1,3)-galactose antibodies in the presence of complement; depleting the line using magnetic beads which are preferably bound with an anti-gal reagent; treating said line with anti-

galactose- $\alpha$  (1,3)-galactose antibodies and then depleting the line using magnetic beads bound to an anti-antibody; and treating said line with gal epitope ligands and then depleting said line with magnetic beads coated with anti ligand antibodies. In certain preferred embodiments, such GGTA I null cell enriching treatment comprises  
5 multiple treatments selected from the group above. In certain preferred embodiments, such GGTA I null cell enriching treatment comprises a combination of multiple treatments selected from the group above. For the purposes of the invention, an "anti-gal reagent" is a reagent which binds to galactose- $\alpha$  (1,3)-galactose and includes but not limited to anti-galactose- $\alpha$  (1,3)-galactose antibody and lectin.

10 In certain preferred embodiments the anti-galactose- $\alpha$  1,3-galactose antibodies are primate antibodies. Antibodies of the invention can be derived from but are not limited to baboon, chimpanzee, gorilla, human and other primates with the ability to produce antibodies to the  $\alpha$ (1,3)-galactosyl-(gal)-epitopes. For the purposes of the invention a "primate" is given its dictionary meaning as defined in Merriam-Webster  
15 (2002) and "includes any of an order (Primates) of mammals comprising humans, apes, monkeys, and related forms (as lemurs and tarsiers). Antibodies of the invention include but are not limited to monoclonal antibodies and fragments thereof. In preferred embodiments, the primate antibody is derived from baboon plasma.

In certain preferred embodiments, the gal epitope ligands include but are not  
20 limited to IB4 conjugates, such as IB4 Biotin (SIGMA, L2140) and IB4-FITC and the anti-ligand antibodies include but are not limited to anti-biotin and anti-FITC.

In certain preferred embodiments, the step of enriching the cell line for GGTA I null cells comprises multiple treatments of anti-galactose- $\alpha$  (1,3)-galactose antibodies in the presence of complement, followed by multiple treatments of depletion using  
25 IB4-FITC and magnetic micro-beads coated with anti-FITC.

All other parameters are as described for the third aspect.

In a fourth aspect, the invention provides GGTA1 null porcine cells that are useful for xenotransplantation. For the purposes of the invention, "GGTA1 null cells" are cells lacking the  $\alpha(1,3)$ -galactosyl-(gal)-epitopes and include but are not limited to cells which are be homozygous, which comprise two disrupted or non-functional GGTA1 genes; hemizygous, which comprise one GGTA1 alleles instead of the usual two alleles for the GGTA1 gene and that the single GGTA1 allele is disrupted or rendered non-functional; or compound heterozygous, which comprise two different mutant alleles for the GGTA1 gene. Such cells are derived from a swine according to the first aspect of the invention. Preferred cells include, without limitation, Islets of Langerhans cells, blood precursor cells, bone precursor cells, and stem cells, including primordial stem cells. More preferably the cell is Q2, Q9, Q32 or Q37 derived therefrom. Such GGTA1 null cells are useful in overcoming hyperacute rejection in primates.

In a fifth aspect, the invention provides porcine organs that are useful for xenotransplantation. Such porcine organs comprise GGTA1 null cells and lack the  $\alpha(1,3)$  galactosyl (gal) epitopes that are responsible for hyperacute rejection in primates. Such organs are derived from a swine according to the first aspect of the invention. For purposes of the invention, an "organ" is an organized structure comprising one or more tissues, which organ performs one or more specific biological function. Preferred organs include, without limitation, heart, liver, kidney, pancreas, lung, thyroid, and skin.

In a sixth aspect, the invention provides tissues that are useful for xenotransplantation. Such tissues lack the  $\alpha(1,3)$  galactosyl (gal) epitopes that are responsible for hyperacute rejection in primates and comprise GGTA1 null cells. Such tissues are derived from a swine according to the first or the second aspect of the invention. For purposes of the invention, a "tissue" is an organized structure comprising cells, which tissue, alone or in conjunction with other cells or tissues, performs one or more biological function.



In a seventh aspect, the invention provides a method for making viable GGTA I null swine. The method according to this aspect of the invention comprises selecting GGTA I null cells, enucleating an oocyte, fusing the oocyte with the GGTA I null cell to yield an NT-derived embryo, and implanting the NT-derived embryo into a surrogate mother, wherein the surrogate mother has initiated estrus, but has not yet completed ovulation.

In certain preferred embodiments, the GGTA I null cells come from a clonal population of GGTA I null cells.

In certain preferred embodiments, the oocyte is obtained from a gilt. In certain preferred embodiments, the oocyte is obtained from a sow. In certain preferred embodiments, the donor cell is a primary fibroblast.

In certain preferred embodiments the donor cell is fused with the enucleated oocyte. Alternatively, the nucleus of the donor cell can be directly injected into the cytoplasm of the enucleated oocyte.

In certain preferred embodiments, the NT-derived embryo is implanted in the uterus of the surrogate mother together with parthenogenetic embryos. Parthenogenetic embryos as used herein mean non-viable embryos i.e. embryos without the ability to further divide and survive through to term. In certain preferred embodiments, the NT-derived embryo is implanted in the uterus of the surrogate mother after the surrogate mother has been bred. In some, but not all preferred embodiments, the oocytes are *in vitro* matured. In some preferred embodiments, the surrogate mother is a gilt. In some preferred embodiments, the surrogate mother is a sow.

In certain preferred embodiments, the oocyte has been enucleated. In certain preferred embodiments, the nucleus of the donor cell is injected into the cytoplasm of the enucleated oocyte.

In certain preferred embodiments, the donor cell is a porcine fetal fibroblast. In certain preferred embodiments, the NT-derived embryo is implanted in the uterus of the non-bred surrogate mother. In some, but not all preferred embodiments, the oocytes are *in vitro* matured.

- 5           In certain preferred embodiments, the donor cell is derived from a porcine fetal fibroblast cell heterozygous for a GGTA1 knockout.

In some preferred embodiments, the surrogate mother is a gilt. In some preferred embodiments, the surrogate mother is a sow.

- 10           In an eighth aspect, the invention provides a method of creating a viable GGTA1 null swine comprising enucleating an oocyte, fusing the oocyte with a cell derived from Q2 to yield an NT-derived embryo, and implanting the NT-derived embryo into a surrogate mother, wherein the surrogate mother has initiated estrus, but has not yet completed ovulation. All other parameters are as described for the eighth aspect.

- 15           In a ninth aspect, the invention provides a method of creating a viable GGTA1 null knockout swine comprising enucleating an oocyte, fusing the oocyte with a cell derived from Q9 to yield an NT-derived embryo, and implanting the NT-derived embryo into a surrogate mother, wherein the surrogate mother has initiated estrus, but has not yet completed ovulation. All other parameters are as described for the eighth aspect.
- 20

- In a tenth aspect, the invention provides a method of creating a viable GGTA1 null swine comprising enucleating an oocyte, fusing the oocyte with a cell derived from Q32 to yield an NT-derived embryo, and implanting the NT-derived embryo into a surrogate mother, wherein the surrogate mother has initiated estrus, but has not yet completed ovulation. All other parameters are as described for the eighth aspect.
- 25

In an eleventh aspect, the invention provides a method of creating a viable GGTA1 null swine comprising enucleating an oocyte, fusing the oocyte with a cell

derived from Q37 to yield an NT-derived embryo, and implanting the NT-derived embryo into a surrogate mother, wherein the surrogate mother has initiated estrus, but has not yet completed ovulation. All other parameters are as described for the eighth aspect.

5        Certain advantageous features of the invention will become evident from the following examples. Cells lacking expression of GGTA1 are useful for the study of cellular processes in the absence of the enzyme, assay of serum reactivity in the absence of  $\alpha$ -1,3-gal epitopes and the generation of GGTA1 null animals. The latter use requires isolation of cells with a stable genetic modification that prevents  
10        expression of the enzyme.

      Previous efforts to isolate GGTA1 null cells beginning with GGTA1 heterozygous cells have utilized transfection with a gene targeting vector combined with a drug selection system that differs from that used to select the heterozygous cells. See Gustaffson et al United States Patent 6,153,428. Development and  
15        application of a second drug selection system has not been successful to date.

      In contrast, the present invention involves selection of cells with mutations in the functional allele of heterozygous GGTA1 cells or somatic recombination leading to GGTA1 null cells without using a second drug selector such as G418. Repeated selection against cells expressing GGTA1 is performed by exposure to affinity  
20        purified primate antibodies against the  $\alpha$ -1,3-gal epitope followed by lysis with complement. As an alternative or supplement treatment, depletion of cells expressing GGTA1 is performed by, with or without first treating the cells with anti-gal reagents, including but not limited to, gal epitope ligands or anti-galactose- $\alpha$ (1,3)-galactose antibodies, followed by using the appropriately coated magnetic micro-beads. The  
25        antibody/complement treatment and the depletion can be repeated multiple times in any order. Use of the above processes results in a population of cells sufficiently enriched in GGTA1 null cells for direct use in nuclear transfer. Alternatively, enriched cell populations may be cloned, with or without additional selection with

antibody and complement or depletion as described above. Similar selection may be performed with other agents which specifically bind the  $\alpha$ -1,3-gal epitope and lead to cell death or permit physical separation of binding and non-binding cell populations.

5       The invention, in conjunction with nuclear transfer, allows for the production of animals containing mutant alleles of the GGTA1 locus that lack foreign DNA sequences. Animals homozygous for such alleles would be preferred for use in clinical xenotransplantation. Alternatively, such alleles would permit additional genetic modifications to be introduced using the same selection system as originally utilized for the isolation of GGTA1 heterozygous cells.

10       The following examples are intended to further illustrate certain particularly preferred embodiments of the invention and are not intended to limit the scope of the invention in any way. Except as otherwise noted, all chemicals are from Sigma (St. Louis, MO).

#### **EXAMPLE 1**

15       **Selection and analysis of cell populations lacking  $\alpha$ -1,3-gal epitope expression**

      The ability to select populations of cells lacking  $\alpha$ -1,3-gal epitope expression was tested by multiple selection of GGTA1 heterozygous 355-F3 cells with anti- $\alpha$ -1,3-gal antibody and complement. GGTA1 heterozygous cells were isolated from a nuclear transfer fetus (355-F3) at day 32 of gestation and cultured as described (Lai et al., Science 295:1089). The donor cells for reconstruction of nuclear transfer embryos leading to the fetuses were explanted and cultured from ear sections of pig O212-2, a GGTA1 heterozygote in which one allele has been inactivated by homologous recombination with vector pGalGTAS-Neo (Lai et al., Science 295:1089, 2002). 355-F3 cells were cultured in F10 medium containing 20% FBS and 20ug/ml gentamycin (media) on collagen I coated dishes at 5%CO<sub>2</sub>, 3%O<sub>2</sub>, and 37°C. Antibodies against  $\alpha$ -1,3-gal epitope were purified from naïve baboon plasma and was adsorbed on  $\alpha$ Gal sugar using the  $\alpha$ -1,3-gal LB-VI matrix column (Alberta Research Council, Canada.)

20

25

The bound antibody was eluted from the column by low pH (0.25% acetic acid, Abbot Labs,) into a TRIS based salt buffer (0.2M TRIS and 0.6M Sodium Chloride.) Eluted fractions were dialyzed against PBS to equilibrate the buffer to PBS. The antibody batch was concentrated in Amicon Centripreps with a cut-off weight of 30K and then  
5 in Centriplus Concentrators with a 50K cut-off weight. The concentrated antibody was dialyzed against PBS, and the concentration determined by UV absorbance and Bradford protein assay. Final stock solutions were diluted to 5 mg/mL and frozen at  $-80^{\circ}\text{C}$ .

The above cell lines were treated in suspension at  $2-3 \times 10^6$  cells/ml in 50-100  
10  $\mu\text{g/ml}$  of affinity purified anti- $\alpha 1,3\text{-gal}$  antibody (Nab) in media for 30 minutes at room temperature with mixing. After washing, cells were then treated with rabbit complement (1:8) (C') containing DNase I ( $10\mu\text{g/ml}$ ) in media for 45 min at room temperature with mixing. Surviving cells were counted and plated in bulk culture, and expanded for subsequent treatments. A total of six Nab/C' treatments were done,  
15 with treatment numbers 1-3 at  $50\mu\text{g/ml}$  anti- $\alpha 1,3\text{-gal}$  antibody and 4-6 at  $100\mu\text{g/ml}$ . Treatments were performed every 7-9 days. Prior to each antibody/complement treatment, cells were analyzed for the presence of  $\alpha\text{-}1,3\text{-gal}$  epitopes with IB4-FITC. Figure 1 shows that initial populations of 355-F3 and PFF-F12 (wild-type fetal fibroblasts) cells stain brightly with the  $\alpha\text{-}1,3\text{-gal}$  epitope specific lectin IB4.  
20 Selection with antibody and complement resulted in 355-F3 derived populations with very little if any specific IB4 staining after 4 treatments. In contrast, selected wild-type cells showed a much lower decrease in mean IB4 staining. In both cases, multiple selections with antibody and complement resulted in populations highly enriched for cells resistant to lysis by additional antibody/complement treatment.  
25 Analysis of 355-F3 derived cells 22 days following the last (6<sup>th</sup>) treatment showed no increase in mean IB4 binding. Similar analysis of PFF-F12 cells 17 days following the last treatment showed a slight increase in mean IB4 binding.

**EXAMPLE 2****Selection and analysis of cell clones lacking wild-type GGTA1 expression**

GGTA1 heterozygous 355-F1 cells were isolated from a nuclear transfer fetus (355-F1) at day 32 of gestation and cultured as described (Lai et al., Science 295:1089). The donor cells for reconstruction of nuclear transfer embryos leading to the fetuses were explanted and cultured from ear sections of pig O212-2, a GGTA1 heterozygote in which one allele has been inactivated by homologous recombination with vector pGalGTΔS-Neo (Lai et al., Science 295:1089, 2002). Cells were cultured in F10 medium containing 20% FBS and 20 µg/ml gentamycin (media) on collagen I coated dishes at 5%CO<sub>2</sub>, 3%O<sub>2</sub>, and 37°C. The cells were then treated with antibody and complement twice in suspension as above prior to plating at low density for isolation of clones lacking α(1,3)-gal epitope expression. After the second treatment, cells were plated at 5 and 10 cells/well in collagen I coated 96well plates. In situ treatments with 100-500 µg/ml anti-α(1,3)-gal antibody for 1 hr 37°C and 1:8 rabbit complement in for 1 hr 37°C were performed every other day for treatments 3-5. Wells containing patches of cells covering greater than 15% of the well were transferred to a 48 well plate and treated the following day in situ with 500 µg/ml anti-α1,3-gal antibody and complement. Cells were passaged for molecular analysis, IB4-FITC analysis, and freezing. RNA and ethanol precipitated DNA were prepared using RNeasy and DNeasy systems from Qiagen. Wells containing viable cells following the last treatment were cultured without further selection and lysis resistant clones analyzed for epitope and RNA expression, as well as GGTA1 locus structure. Analysis of two representative clones, Q2 and Q9, is shown in Figures 2 and 3. Both clones had little or no specific IB4 binding (Figure 2). Approximately 50 ng of Q2 and Q9 RNA was reversed transcribed into cDNA using AMV Reverse Transcriptase XL (Takara Shuzo Co., Ltd.) cDNA was then amplified in reactions using LA Taq DNA polymerase (Takara Shuzo Co., Ltd.), the GGTA1 exon 2 forward primer GT-598 (5'-TTCTGCAGAGCAGAGCTCAC) and the exon 9 reverse primer RN1 (5'-CCCTCAACCCAGAACAGATAAG). PCR products were analyzed on a 1%

gel. Southern blots of the RT-PCR products were hybridized to oligonucleotide R823 (5'-AGGATGTGCCTTGTACCACC ), which detects transcripts derived from both gene targeted and native GGTA1 loci. A 1421 base pair band is expected for the native locus and 2472 base pair band for the targeted locus. RT-PCR analysis of the clones (Figure 3) resulted in a band compatible with expression from the gene targeted locus present in Q2 and Q9 cells, but no band compatible with expression from a wild-type GGTA1 locus. Approximately 200 ng of DNA was amplified, cut and analyzed on agarose gels as described (Lai et al., Science 295:1089), except that the 5' genomic assay utilized primers F248 (5'-

10 GAAGAAGACGCTATAGGCAACG ) and RN1 in place of F238 and R823. To increase sensitivity of detection, DNA from the gels was transferred to nylon membranes and hybridized to oligonucleotide probe R823 as above. Hybridizing Eco RI bands of approximately 2550 bp and 3600 bp are expected in the 5' genomic assay from native and targeted GGTA1 loci respectively. Hybridizing Sac I bands of

15 approximately 1250 bp and 2300 bp are expected in the 3' genomic assay from native and targeted GGTA1 loci respectively. Genomic PCR analysis (Figure 3), revealed the presence of a GGTA1 locus with a structure expected from the gene targeted locus in 355-F1 cells, but no locus with a structure like that of the wild-type GGTA1 locus.

### EXAMPLE 3

#### 20 Production of piglets using cell clones lacking wild-type GGTA1 expression

Nuclear transfer was performed using clonal cell lines Q2 and Q9 (described above) and lines Q32 and Q37, produced at the same time using the same methodology. Figure 4 shows a genomic southern blot of DNA from the four clones hybridized to a probe from the GGTA1 gene, confirming the absence of a wild-type

25 GGTA1 allele in all of the cloned cell lines. Embryos reconstructed by nuclear transfer using the Q32 cell line were transferred to 6 surrogate gilts, 3 of which established pregnancies as determined by ultrasound examination. One of these pregnancies continued to term and delivered two piglets following caesarian section (piglets O177-1 and O177-2).

Genomic southern blot analysis of DNA prepared from ear fibroblasts confirmed the absence of a wild-type GGTA1 allele in both piglets (Figure 5). Expression of  $\alpha$ -1,3-gal epitopes in ear fibroblasts of piglet O177-1 was examined by flow cytometric analysis following staining with IB4-FITC and was negative, confirming the absence of  $\alpha$ -1,3-galactosyltransferase activity in this GGTA1 null animal (Figure 6). A photograph of piglet O177-1 at 2 months of age is included as Figure 7.

#### **EXAMPLE 4**

##### **Selection and analysis of cell clones lacking wild type GGTA1 expression following depletion using magnetic micro-beads**

15541 fibroblasts were obtained from ear punches of GGTA1 heterozygous piglet 15541 by enzymatic digestion as previously described.  $2 \times 10^7$  cells, at a concentration of  $2 \times 10^6$  cells/ml, were stained for 10 minutes at 37°C with 2  $\mu$ g/ml of IB4-Biotin (SIGMA, L2140) in IB4 Isolation Buffer (1 X PBS containing magnesium and calcium, 0.5% dialyzed BSA). The cells were then washed twice with the isolation buffer and centrifuged for 5 minutes at 200x g. The cells were adjusted to  $1.25 \times 10^8$  cells/ml in isolation buffer and anti-biotin micro beads (Miltenyi Biotec, 130-090-485) were added at 20  $\mu$ l per  $10^7$  cells. The bead and cell mixture was incubated for 30 minutes at 4°C, with agitation every 10 minutes. Cells were washed with the isolation buffer and centrifuged for 5 minutes at 200x g. Cells were then suspended in 0.5ml of isolation buffer and passed through a 40 micron straining filter. The filter was rinsed with an additional 0.5 ml of isolation buffer and the cells applied to a MACS LD (Miltenyi Biotec, 130-042-901) depletion column with the appropriate magnet. The flow through was collected as the putative gal epitope negative cell population and subcloned at 1/3 cell per well into collagen I coated 96 well microtiter plates. Cell clones were isolated 11-14 days later and expanded for analysis and cryopreservation.



Clones 15541.25 and 15541.63 were examined for expression of gal epitopes by flow cytometric analysis following staining with FITC conjugated IB4 lectin (Figure 8). Fluorescence for both clones was indistinguishable from that seen without IB4-FITC staining.

5 DNA was prepared from clones 15541.25 and 15541.63 and analyzed by 3' genomic PCR analysis as described for Figure 3B (Figure 9). Clone 15541.25 was found to contain a single gene targeted allele and a second allele similar in size to a wild-type allele; the exact nature of the GGTA1 mutation in this clone has not been determined. Clone 15541.63 was found to lack a wild-type GGTA1 allele, as seen  
10 previously with GGTA1 null cell clones Q2, Q9, Q32 and Q37.

### **EXAMPLE 5**

#### **Production of piglets using uncloned cell populations depleted of gal epitope bearing cells**

Cells from GGTA1 heterozygous fetus PF1510 were subjected to 3 rounds of  
15 antibody/complement lysis as described in Example 1, followed by 3 rounds of depletion using IB4-FITC and anti-FITC magnetic micro-beads as described in Example 4. IB4-FITC staining of the depleted cell population (PF1510 NullIB cells) is shown in Figure 10.

Nuclear transfer was performed using PF1510 NullIB cells as the donor line.  
20 Embryo recipient 1538 delivered one surviving piglet, PL751 (Figure 11). Analysis of genomic DNA from this piglet confirmed the absence of a WT GGTA1 allele, as seen previously with piglets derived from clonal cell lines selected with natural antibody and complement (Figure 12). Flow analysis of ear fibroblasts from PL751 also revealed the absence of IB4 lectin staining cells (Figure 13).

1   What is claimed is:

2   1.   A viable GGTA1 null swine.

1   2.   A swine according to claim 1 wherein the swine is a miniature swine.

1   3.   A method of selecting GGTA1 null cells comprising the steps of:

2       (a)   obtaining a line of cells obtained from a GGTA1 heterozygous pig or  
3            fetus;

4       (b)   enriching the cells for GGTA1 null cells; and

5       (c)   scanning the line for viable GGTA1 null cells.

1   4.   The method of claim 3 wherein in step (b), the cells are enriched by at least one  
2       treatment selected from the group consisting of:

3       (a)   treating the said cells with anti-galactose- $\alpha$ (1,3)-galactose antibodies, in  
4            the presence of complement;

5       (b)   depleting the said cells with magnetic micro-beads bound with anti-gal  
6            reagents;

7       (c)   treating the said cells with anti-galactose- $\alpha$ (1,3)-galactose antibodies and  
8            depleting the said cells with magnetic micro-beads bound with anti-  
9            antibodies; and

10      (d)   treating the said line with gal epitope ligands and depleting the said line  
11         with magnetic micro-beads bound with anti ligand antibodies.

1   5.   The method of claim 3 wherein in step (b), the cells are enriched by multiple  
2       treatments selected from the group consisting of:

- 3 (a) treating the said cells with anti-galactose- $\alpha$ (1,3)-galactose antibodies, in  
4 the presence of complement;
- 5 (b) depleting the said cells with magnetic micro-beads bound with anti-gal  
6 reagents;
- 7 (c) treating the said cells with anti-galactose- $\alpha$ (1,3)-galactose antibodies and  
8 depleting the said cells with magnetic micro-beads bound with anti-  
9 antibodies; and
- 10 (d) treating the said cells with gal epitope ligands and depleting the said line  
11 with magnetic micro-beads bound with anti ligand antibodies.
- 1 6. The method of claim 3 wherein in step (b), the cells are enriched by three  
2 treatments of each of the following:
- 3 (a) treating the said cells with anti-galactose- $\alpha$ (1,3)-galactose antibodies, in  
4 the presence of complement;
- 5 (b) treating the said cells with gal epitope ligands and depleting the said line  
6 with magnetic micro-beads bound with anti ligand antibodies.
- 1 7. The method according to any of claims 3-6 wherein the line of cells is a line of  
2 porcine fetal fibroblast cells.
- 1 8. The method according to any of claims 3-6 wherein the line of cells is a clonal  
2 population of porcine fetal fibroblast cells.
- 1 9. The method of claim 7 or 8 wherein the porcine fetal fibroblast cells originate  
2 from miniature swine.
- 1 10. The method according to claim any of claims 3-6 wherein the line of cells is a  
2 line of stem cells.

- 1 11. The method of claim 10 wherein the stem cells are primordial stem cells.
- 1 12. The method according to any of claims 4-6 wherein the anti-galactose- $\alpha$ (1,3)-  
2 galactose antibodies are primate antibodies.
- 1 13. The method according to any of claims 4-6 wherein the anti-galactose- $\alpha$ (1,3)-  
2 galactose antibodies are monoclonal antibodies or fragments thereof.
- 1 14. The method according to any of claims 4-5, wherein the anti-gal reagents are  
2 selected from a group consisting of anti-galactose- $\alpha$ (1,3)-galactose antibodies  
3 and lectin.
- 1 15. The method according to any of 4-6, wherein the gal epitope ligands are IB4  
2 conjugates and the anti-epitope ligands are anti-IB4 conjugates.
- 1 16. The method according to claim 15 wherein the IB4 conjugates are selected from  
2 a group consisting of IB4 biotin and IB4-FITC and the anti-IB4 conjugates are  
3 selected from a group consisting of anti-biotin and anti-FITC.
- 1 17. A porcine GGTA1 null cell.
- 1 18. The porcine cell according to claim 17 wherein the said cell is homozygous for  
2 the GGTA1 gene, and wherein the said GGTA1 gene is disrupted or rendered  
3 non-functional.
- 1 19. The porcine cell according to claim 17 wherein the said cell is hemizygous for  
2 the GGTA1 gene, and wherein the only single GGTA1 allele is disrupted or  
3 rendered non-functional.
- 1 20. The porcine cell according to claim 17 wherein the said cell is compound  
2 heterozygous for the GGTA1 gene, and wherein the said GGTA1 gene  
3 comprises two different mutant alleles.
- 1 21. The porcine cell according to claim 17 wherein the said cell is from Q2.

- 1 22. The porcine cell according to claim 17 wherein the said cell is from Q9.
- 1 23. The porcine cell according to claim 17 wherein the said cell is from Q32.
- 1 24. The porcine cell according to claim 17 wherein the said cell is from Q37.
- 1 25. A porcine organ lacking expression of galactose- $\alpha$ (1,3)-galactose epitopes.
- 1 26. A porcine organ according to claim 26 wherein the said organ comprises cells  
2 homozygous for the GGTA1 gene, and wherein the said GGTA1 gene is  
3 disrupted or rendered non-functional.
- 1 27. A porcine organ according to claim 26 wherein the said organ comprises cells  
2 hemizygous for the GGTA1 gene, and wherein the only single GGTA1 allele is  
3 disrupted or rendered non-functional.
- 1 28. A porcine organ according to claim 26 wherein the said organ comprises cells  
2 which are compound heterozygote for the GGTA1 gene, and wherein the said  
3 GGTA1 gene comprises two different mutant alleles.
- 1 29. The porcine organ according to any of claims 25-28 wherein the porcine organ  
2 is selected from a group comprising heart, liver, kidney, pancreas, thyroid and  
3 skin.
- 1 30. Porcine tissues lacking expression of galactose- $\alpha$ 1,3-galactose epitopes.
- 1 31. Porcine tissues according to claim 30 wherein said tissues comprise cells  
2 homozygous for the GGTA1 gene, and wherein the said GGTA1 gene is  
3 disrupted or rendered non-functional.
- 1 32. Porcine tissues according to claim 30 wherein said tissues comprise cells  
2 hemizygous for the GGTA1 gene, and wherein the only single GGTA1 allele is  
3 disrupted or rendered non-functional.

- 1 33. Porcine tissues according to claim 30 wherein said tissues comprise cells which  
2 are compound heterozygote for the GGTA1 gene, and wherein the said GGTA1  
3 gene comprises two different mutant alleles.
- 1 34. A method of creating a viable GGTA1 null swine comprising selecting GGTA1  
2 null cells, enucleating an oocyte, fusing the oocyte with the said GGTA1 null  
3 cell to yield an NT-derived embryo, and implanting the NT-derived embryo into  
4 a surrogate mother, wherein the surrogate mother has initiated estrus, but has not  
5 yet completed ovulation.
- 1 35. The method according to claim 34 wherein the GGTA1 null cells are derived  
2 from a line of porcine fetal fibroblast cells.
- 1 36. The method according to claim 34 wherein the GGTA1 null cells are derived  
2 from a clonal population of porcine fetal fibroblast cells.
- 1 37. The method of claim 35 or 36 wherein the porcine fetal fibroblast cells originate  
2 from miniature swine.
- 1 38. The method of claim 35 or 36 wherein the porcine fetal fibroblasts cells are  
2 heterozygous for a GGTA1 knockout.
- 1 39. The method according to claim 34 wherein the GGTA1 null cells are derived  
2 from Q2.
- 1 40. The method according to claim 34 wherein the GGTA1 null cells are derived  
2 from Q9.
- 1 41. The method according to claim 34 wherein the GGTA1 null cells are derived  
2 from Q32.
- 1 42. The method according to claim 34 wherein the GGTA1 null cells are derived  
2 from Q37.

Figure 1




Figure 2






Figure 3A.

1 2 3 4



— 4.4 —


— 2.3 —

— 2.0 —

— .56 —

Figure 3B.

1 2 3 4 5 6 7 8 9



— 4.4 —

— 2.3 —

— 2.0 —

— .56 —

Figure 4.




Figure 5.




Figure 6.




Figure 7.



Figure 8.




Figure 9.





Figure 10.



PF1510 NullB cells, unstained

PF1510 NullB cells, IB4-FITC stained



Figure 11.



Figure 12.






Figure 13.

PL751

- IB4-FITC



+ IB4-FITC



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINE(S) OR MARK(S) ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**